Home/ISRN Ophthalmology/Article Record
Peer-Reviewed Article July 6, 2013

New Therapeutic Targets for Intraocular Pressure Lowering

Are you an author of this work?Link to your sovereign AfriScholar profile
Published in: ISRN Ophthalmology
Publisher: Hindawi Publishing Corporation • Egypt • 2090-5688
DOI: https://doi.org/10.1155/2013/261386

Abstract

Primary open-angle glaucoma (POAG) is a leading cause of irreversible and preventable blindness and ocular hypertension is the strongest known risk factor. With current classes of drugs, management of the disease focuses on lowering intraocular pressure (IOP). Despite of their use to modify the course of the disease, none of the current medications for POAG is able to reduce the IOP by more than 25%-30%. Also, some glaucoma patients show disease progression despite of the therapeutics. This paper examines the new described physiological targets for reducing the IOP. The main cause of elevated IOP in POAG is thought to be an increased outflow resistance via the pressure-dependent trabecular outflow system, so there is a crescent interest in increasing trabecular meshwork outflow by extracellular matrix remodeling and/or by modulation of contractility/TM cytoskeleton disruption. Modulation of new agents that act mainly on trabecular meshwork outflow may be the future hypotensive treatment for glaucoma patients. There are also other agents in which modulation may decrease aqueous humour production or increase uveoscleral outflow by different mechanisms from those drugs available for glaucoma treatment. Recently, a role for the ghrelin-GHSR system in the pathophysiology modulation of the anterior segment, particularly regarding glaucoma, has been proposed.

Download Full Text PDFView at PublisherCrossref RecordCrossref XML

Verified Citation Velocity

Recorded scholarly citations in African and international peer-reviewed literature

40
Total Citations

Citations are continuously tracked and harvested across continental OJS endpoints and OpenAlex feeds.